Loading search results
HERITOPK
Sponsor study identifier
Secondary identifiers
OTHER · ID-RCB number, ANSM
observational
58
1 country
1
Study Start
April 20, 2018
Actual (reported)Primary Completion
June 2, 2022
Actual (reported)Study Completion
June 2, 2022
Actual (reported)Polycystic ovary syndrome (PCOS) is the most common cause of ovulation disorders and affects 10 to 15% of women. Despite its frequency, its physiopathology remains unknown. In women, Anti-Müllerian hormone (AMH) is secreted by granulosa cells located in the ovaries within the follicles. Compared to control women, serum AMH level is higher in PCOS women and could play a role in its pathophysiology. The severity of the PCOS phenotype is correlated with the production of AMH. It is currently described in the literature that daughters of women with PCOS have a 50% risk of developing PCOS, but no genetic cause of transmission is known. In mice (article in press), pregnant females injected with AMH give birth to offspring with PCOS symptoms. The AMH could thus also play a role in the heritability of PCOS in women. Our team demonstrated that AMH, in its active cleaved form, had a direct central action on the hypothalamus by increasing the pulsatility of GnRH, inducing LH hypersecretion. The hypothesis is that AMH remains higher in pregnant women with PCOS and may affect the fetus by altering fetal and maternal hypothalamic secretions or by modifying placental steroid production. Leptin has a role in reproduction, through its receptors located at the central (hypothalamus) and peripheral (granulosa cells) levels. In excessively high serum concentration, as observed in obesity, it would lead to a dysregulation of GnRH secretion, an alteration of ovarian steroidogenesis and a dysregulation of folliculogenesis. Will be compare leptin levels in first trimester patients with and without PCOS to look for possible correlations between AMH and leptin and eliminate possible bias.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 2, 2022
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 14, 2018
Actual (reported)March 30, 2018
Actual (reported)April 20, 2018
Actual (reported)June 2, 2022
Actual (reported)June 2, 2022
Actual (reported)Rate of plasma AMH in the 3rd trimester of pregnancy
between 29 and 44 amenorrhea weeks
The variation of maternal plasma AMH
At baseline, between 5 and 15 amenorrhea weeks, between 15+1 day and 28+ 6 days amenorrhea weeks, between 29 and 44 amenorrhea weeks
The percentage change in the different forms of AMH (pro-AMH and cleaved forms)
At baseline, between 5 and 15 amenorrhea weeks, between 15+1 day and 28+ 6 days amenorrhea weeks, between 29 and 44 amenorrhea weeks
The variation in oestradiol, testosterone and LH levels
At baseline, between 5 and 15 amenorrhea weeks, between 15+1 day and 28+ 6 days amenorrhea weeks, between 29 and 44 amenorrhea weeks
The rate of leptin (only dosage in fasting patients)
between 5 and 15 amenorrhea weeks
The level of expression of aromatase, AMH and AMH Receptor II in the placenta
at delivery
4 x 7 ml of blood punction at each control visit of the three trimesters of pregnancy
Immediately following delivery (\<12h postpartum), placental biopsies (Collection of 4 placental fragments)
Patients having a pre-conceptionnal infertility assessment in the gynecology-Endocrinology department of the CHRU of Lille, in the first trimester of monofetal pregnancy (between 5 and 10 weeks of gestation), obtained spontaneously, after induction of ovulation or Assisted Reproductive Techniques (ART)
Hôpital Jeanne de Flandres, CHU
Lille, France
Peigne M, Simon V, Pigny P, Mimouni NEH, Martin C, Dewailly D, Catteau-Jonard S, Giacobini P. Changes in circulating forms of anti-Muullerian hormone and androgens in women with and without PCOS: a systematic longitudinal study throughout pregnancy. Hum Reprod. 2023 May 2;38(5):938-950. doi: 10.1093/humrep/dead050.
plasma placenta fragment
Sophie Catteau-Jonard, MD,PhD
University Hospital, Lille
58 participants (actual enrollment reported by the registry).
First Submitted
February 14, 2018
First Posted
March 30, 2018
Study Start
April 20, 2018
Actual (reported)Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
June 2, 2022
Actual (reported)Study Completion
June 2, 2022
Actual (reported)Last Updated
December 23, 2025
Record last verified: 2025-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: